TORONTO--(BUSINESS WIRE)--Mednow Inc. (“Mednow” or the “Company”) (TSXV: MNOW) (OTCQX: MDNWF) announced today the launch of its enhanced Virtual Diabetes Management program, an end-to-end digital ...
StockStory.org on MSN
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an ...
The clearance comes as multiple diabetes tech products are planned to be released this year. However, slower FDA reviews have delayed certain product launches, such as the much-anticipated Insulet ...
In honor of National Diabetes Awareness Month, DAV (Disabled American Veterans) announced today a new strategic partnership with Dexcom, the global leader in glucose biosensing. As part of the ...
Dexcom has received FDA approval for a continuous glucose monitor (CGM) that integrates with insulin pumps and other diabetes devices. The regulatory clearance marks the first time the FDA has signed ...
Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings tomorrow after the bell. Here’s what investors should know. DexCom met analysts’ revenue expectations last quarter, reporting ...
Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A strong first-quarter 2025 performance and a series of favorable coverage decisions are ...
DexCom stock (NASDAQ: DXCM) currently trades at $73 per share, around 55% below the highs of $163 seen in November 2021. In comparison, Insulet stock (NASDAQ: PODD) saw its stock decline 39% over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback